Genenta Science S.p.A.
Business
Genenta Science S.p.A. is a clinical-stage biotechnology company developing autologous ex-vivo hematopoietic stem cell gene therapies for the treatment of solid tumors, currently focused on glioblastoma multiforme. The company's proprietary platform uses lentiviral vectors to genetically modify patients' own stem cells to deliver immunomodulatory payloads (such as interferon-alpha) directly to tumors via Tie2-expressing monocytes. Genenta operates as a single clinical-stage biotech company with its lead candidate, Temferon, in a paused Phase 1/2a trial; the company announced in January 2026 a strategic transformation to become an industrial consolidator in national-security-regulated sectors, though it remains primarily engaged in gene therapy development.
Summary from 20-F filed 2026-04-01
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-6.50M |
| Total assets | $31.89M |
| Total liabilities | — |
| Stockholders' equity | $21.84M |
| Operating cash flow | $-6.87M |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Genenta Science S.p.A.'s CIK number?
Genenta Science S.p.A.'s SEC CIK number is 0001838716 (1838716). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Genenta Science S.p.A.'s SEC filings?
All of Genenta Science S.p.A.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.